ClearPoint Neuro Inc vs Eos Energy Enterprises Inc — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Eos Energy Enterprises Inc trades at $4.31 (market cap $1.52B). The key difference: Eos Energy Enterprises Inc is far larger — about 3.2× ClearPoint Neuro Inc's market cap, and ClearPoint Neuro Inc is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | EOSE | |
|---|---|---|
Market Cap | $478.63M | $1.52B |
Sector | Health | Energy |
52-Week High | $29.60 | $19.19 |
52-Week Low | $8.66 | $4.29 |
Enterprise Value | $506.63M | $1.75B |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Eos Energy Enterprises (EOSE) trades at $4.35, down 1.14% on the day, amid a bearish technical trend and challenging fundamentals. The company reported a net loss of $969.65 million on $114.20 million in revenue for 2025, with negative gross and net profit margins. However, recent news highlights project wins, including a 400 MWh battery storage selection, and a $125 million investment for its Frontier Power USA platform, signaling growth potential in the long-duration energy storage market.
The outlook is a balance of high execution risk against significant growth opportunity. While analyst consensus is a 'Hold' with a $8.40 price target, the company's path to profitability remains uncertain. Key risks include persistent cash burn and high debt-to-asset ratio, but successful commercialization of its zinc-based battery technology could drive substantial upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →